Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal

Autores da FMUP

• Paula Isabel Marques Simões De Freitas

  Autor

Participantes de fora da FMUP

• Miguel, Luis Silva
• Soares, Mariana
• Olivieri, Anamaria
• Sampaio, Filipa
• Lamotte, Mark
• Shukla, Suramya
• Conde, Vasco
• Costa, Joao
• Borges, Margarida

Unidades de investigação

• Medicina

Abstract

Background Obesity and overweight are a significant public health concern. Subcutaneous semaglutide 2.4 mg injection is a glucagon-like peptide-1 (GLP-1) analogue approved by the European Medicines Agency as an adjunct to a reduced calorie diet and increased physical activity (diet and exercise, D&E) for the treatment obesity and overweight in the presence of at least one weight related comorbidity. This study aimed to assess the cost-effectiveness of semaglutide 2.4 mg in combination with D&E compared to D&E alone for the Portuguese setting.Methods Analysis were conducted using the Core Obesity Model (COM) version 18, a Markov state transition cohort model, to predict the health outcomes and costs of weight related complications based on changes in surrogate endpoints. Efficacy and safety data were sourced from the STEP trials (Body Mass Index, systolic blood pressure and glycemic status) from a cohort of adults aged on average 48 years with obesity (BMI >= 30 kg/m2) and >= 1 obesity-related comorbidities, over a time horizon of 40 years. Costs were estimated from the perspective of the Portuguese National Health Service. Sensitivity analyses were conducted to test the robustness of results across a range of assumptions.Results On a patient level, Semaglutide 2.4 mg in addition to D&E compared to D&E alone, improved QALYs by 0.098 and yielded higher costs by 1,325 EUR over a 40-year time horizon, with an ICER of 13,459 EUR per QALY gained and 100% probability of cost-effectiveness at the given WTP. Semaglutide 2.4 mg remained cost-effective across all different scenarios and sensitivity analysis at a WTP of 20,000 EUR per QALY. Among the subpopulations examined, Semaglutide 2.4 mg yielded ICERs of 18,459 EUR for patients with BMI >= 30 kg/m2 and of 22,657 EUR for patients with BMI >= 35 kg/m2.Conclusions Semaglutide 2.4 mg was cost-effective compared to D&E alone for patients with obesity (BMI >= 30 kg/m2) and weight related comorbidities in Portugal, over a 40-year time horizon.

Keywords

• Cost-effectiveness analysis; Obesity; Semaglutide 2.4 mg; Portugal